These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
349 related articles for article (PubMed ID: 26565382)
1. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7. Chohan TA; Qian HY; Pan YL; Chen JZ Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382 [TBL] [Abstract][Full Text] [Related]
2. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations. Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408 [TBL] [Abstract][Full Text] [Related]
3. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors. Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105 [TBL] [Abstract][Full Text] [Related]
4. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6. Liang JD; Zhang YE; Qin F; Chen WN; Jiang WM; Fang Z; Liang XL; Zhang Q; Li J J Cancer Res Clin Oncol; 2024 Jun; 150(6):302. PubMed ID: 38856753 [TBL] [Abstract][Full Text] [Related]
5. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors. Zhang G; Ren Y Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939 [TBL] [Abstract][Full Text] [Related]
6. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors. Tripathi SK; Muttineni R; Singh SK J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278 [TBL] [Abstract][Full Text] [Related]
7. Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations. Chen J; Pang L; Wang W; Wang L; Zhang JZH; Zhu T J Biomol Struct Dyn; 2020 Mar; 38(4):985-996. PubMed ID: 30843759 [TBL] [Abstract][Full Text] [Related]
8. Exploring the selectivity of a ligand complex with CDK2/CDK1: a molecular dynamics simulation approach. Tripathi SK; Singh SK; Singh P; Chellaperumal P; Reddy KK; Selvaraj C J Mol Recognit; 2012 Oct; 25(10):504-12. PubMed ID: 22996593 [TBL] [Abstract][Full Text] [Related]
9. Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines. Hylsová M; Carbain B; Fanfrlík J; Musilová L; Haldar S; Köprülüoğlu C; Ajani H; Brahmkshatriya PS; Jorda R; Kryštof V; Hobza P; Echalier A; Paruch K; Lepšík M Eur J Med Chem; 2017 Jan; 126():1118-1128. PubMed ID: 28039837 [TBL] [Abstract][Full Text] [Related]
10. Insights into the structural basis of 3,5-diaminoindazoles as CDK2 inhibitors: prediction of binding modes and potency by QM-MM interaction, MESP and MD simulation. Tripathi SK; Singh SK Mol Biosyst; 2014 Aug; 10(8):2189-201. PubMed ID: 24909777 [TBL] [Abstract][Full Text] [Related]
11. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4. Park H; Yeom MS; Lee S Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811 [TBL] [Abstract][Full Text] [Related]
12. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design. Shen M; Zhou S; Li Y; Li D; Hou T Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors. Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773 [TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of various electrostatic potentials on docking precision against cyclin-dependent kinase 2 protein: a multiple docking approach. Tripathi SK; Soundarya RN; Singh P; Singh SK Chem Biol Drug Des; 2015 Feb; 85(2):107-18. PubMed ID: 24923208 [TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors. Pasha FA; Neaz MM J Mol Model; 2013 Feb; 19(2):879-91. PubMed ID: 23086460 [TBL] [Abstract][Full Text] [Related]
16. Quantum mechanical scoring: structural and energetic insights into cyclin-dependent kinase 2 inhibition by pyrazolo[1,5-a]pyrimidines. Brahmkshatriya PS; Dobeš P; Fanfrlik J; Rezáç J; Paruch K; Bronowska A; Lepšík M; Hobza P Curr Comput Aided Drug Des; 2013 Mar; 9(1):118-29. PubMed ID: 23157414 [TBL] [Abstract][Full Text] [Related]
17. Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study. Hazel P; Kroll SH; Bondke A; Barbazanges M; Patel H; Fuchter MJ; Coombes RC; Ali S; Barrett AG; Freemont PS ChemMedChem; 2017 Mar; 12(5):372-380. PubMed ID: 28125165 [TBL] [Abstract][Full Text] [Related]
18. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy. Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444 [TBL] [Abstract][Full Text] [Related]
19. Exploring the mechanism of action of spirooxindoles as a class of CDK2 inhibitors: a structure-based computational approach. Abdjan MI; Shafiq M; Nerukh D; Nur-E-Alam M; Ul-Haq Z Phys Chem Chem Phys; 2024 Jun; 26(22):16139-16152. PubMed ID: 38787638 [TBL] [Abstract][Full Text] [Related]
20. Accurate Prediction of Complex Structure and Affinity for a Flexible Protein Receptor and Its Inhibitor. Bekker GJ; Kamiya N; Araki M; Fukuda I; Okuno Y; Nakamura H J Chem Theory Comput; 2017 Jun; 13(6):2389-2399. PubMed ID: 28482660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]